Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.71 USD
-0.05 (-2.84%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Esperion Therapeutics (ESPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.08 | $16.00 | $2.50 | 359.09% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Esperion Therapeutics comes to $8.08. The forecasts range from a low of $2.50 to a high of $16.00. The average price target represents an increase of 359.09% from the last closing price of $1.76.
Analyst Price Targets (6 )
Broker Rating
Esperion Therapeutics currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 57.14% and 14.29% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 2 | 2 | 3 |
Sell | 1 | 1 | 1 | 1 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 2.00 | 2.00 | 1.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/28/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
6/28/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/2/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Thomas Shrader | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $8.08 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 102 of 253 |
Current Quarter EPS Est: | -0.16 |